本报（chinatimes.net.cn）记者张斯文 于娜 北京报道 东阿阿胶在业绩增长的表象下，却遭遇了市场信心的动摇，股价走势与行业趋势形成鲜明反差，折射出 投资者对其经营模式的深层担忧。 公司对核心产品的高度依赖，不仅加剧了市场竞争带来的压力，也暴露了其在产品多元化布局上的滞 后，抗风险能力面临考验。 业绩增长股价反而下跌 一份营收净利双增长的中报背后，以及高达99.94%的利润分红比例，仍不能挽救东阿阿胶 （000423.SZ）的股价。 2025年4月末，东阿阿胶股价达到了年内最高区间，股价在60元/股左右。但自从公司公布业绩"双增"的 一季报后，股价反而吃了个跌停。 自此，东阿阿胶股价转头向下。 在中国城市发展研究院、农文旅产业振兴研究院常务副院长袁帅看来，与片仔癀分红率50%且研发投入 8%相比，东阿阿胶的高分红策略显得有些短视。 他对《华夏时报》记者表示，财务健康与战略风险方面，2025年中报显示东阿阿胶类现金资产达87亿 元，占总资产的68%，却选择将99.94%的净利润用于分红，而非加大研发投入。虽然高分红能在短期内 吸引投资者，但从长期来看，缺乏研发投入会导致产品创新不足，难以适应市场变化 ...

Core Viewpoint - Dong-E E-Jiao demonstrates a strong commitment to shareholder returns through substantial cash dividends, with a mid-year profit distribution of 817 million yuan, reflecting a dividend yield significantly higher than bank deposit rates [1][11]. Group 1: Dividend Distribution - The company announced a mid-year profit distribution plan of 12.69 yuan per 10 shares, totaling 817 million yuan, which accounts for 99.94% of its net profit for the first half of 2025 [1]. - Since its listing in 1996, Dong-E E-Jiao has maintained a generous dividend policy, with cumulative dividends reaching approximately 9.287 billion yuan [2][3]. - After the upcoming mid-year dividend, the total dividends will exceed 10.104 billion yuan, marking a significant milestone for the company [4][5]. Group 2: Financing and Dividend Ratio - Dong-E E-Jiao has only conducted three rounds of financing since its IPO, raising a total of 505 million yuan, which is significantly lower than its cumulative dividend payouts [6]. - The total dividend amount of 10.104 billion yuan is 20 times the total financing amount, indicating a strong dividend financing ratio [7]. Group 3: Commitment to Shareholder Returns - The company has shown resilience in maintaining dividends even during challenging times, such as in 2019 when it reported a net loss of 444 million yuan but still distributed dividends [9]. - The evolving regulatory environment and investor expectations have contributed to a greater emphasis on dividends among listed companies in China [9]. Group 4: Financial Performance and Investment Value - For the first half of 2025, Dong-E E-Jiao reported a revenue of 3.051 billion yuan, a year-on-year increase of 11.02%, and a net profit of 818 million yuan, up 10.74% [11]. - The company boasts a low debt ratio of 19.17% and a strong cash flow position, with cash and financial assets totaling 8.739 billion yuan [11]. - Dong-E E-Jiao's high dividend strategy is supported by its robust cash flow generation capabilities and low debt structure, reflecting confidence in its future growth [11].

Core Viewpoint - Dong'e Ejiao demonstrated strong growth in the first half of 2025, with all key indicators showing steady improvement, further solidifying its competitive position in the market [1] Financial Performance - In the first half of 2025, Dong'e Ejiao achieved operating revenue of 3.051 billion yuan, a year-on-year increase of 11.02% [2] - The net profit attributable to shareholders reached 818 million yuan, up 10.74% year-on-year, while the net profit after deducting non-recurring gains and losses was 788 million yuan, reflecting a 12.58% increase [2] - The net cash flow from operating activities was 965 million yuan, a 4.70% increase, with the second quarter showing a significant recovery at 1.270 billion yuan [2] - The company's earnings per share for the first half was 1.2698 yuan, an increase of 10.52% [2] - As of the end of June, the asset-liability ratio was 19.17%, indicating low debt risk and an optimized financial structure [2] Dividend Policy - Dong'e Ejiao announced a mid-term dividend plan, proposing a cash dividend of 12.69 yuan per 10 shares, totaling approximately 817 million yuan, which accounts for 99.94% of the net profit attributable to shareholders for the first half of 2025 [3] - Since its first dividend in 1999, the company has cumulatively distributed 10.104 billion yuan, with an average payout ratio of nearly 70% [3] Product Performance and Brand Value - The core product matrix contributed significantly to performance, with revenue from Ejiao and related products reaching 2.845 billion yuan, a year-on-year increase of 11.50% [4] - The market share of Dong'e Ejiao blocks was 67.3%, maintaining its leadership in the OTC market [4] - The company was recognized as one of the first "Chinese Consumer Famous Brands" by the Ministry of Industry and Information Technology, and its brand value increased to 49.697 billion yuan, ranking 245th in the "China's 500 Most Valuable Brands" list [4] Strategic Initiatives and Future Growth - Dong'e Ejiao is transitioning from a single-product focus to a health ecosystem platform, implementing the "Royal Weichang 1619" strategy to enter the men's health supplement market [5] - The company has established a 1 billion yuan pharmaceutical industry investment fund, with Dong'e Ejiao contributing 60 million yuan for a 6% stake, focusing on traditional Chinese medicine and synthetic biology [5] - The company is advancing its stock incentive plan, having completed the first grant registration of the restricted stock incentive plan, which aims to enhance talent retention and strategic execution [5]

Core Insights - Dong'e Ejiao reported a revenue of 3.051 billion yuan for the first half of 2025, representing a year-on-year growth of 11.02% [1] - The net profit reached 818 million yuan, up 10.74% year-on-year, while the net profit after deducting non-recurring items was 788 million yuan, increasing by 12.58% [1] - The company continues to optimize its financial structure and operational efficiency, focusing on high-margin product categories and reducing donkey-hide inventory [1][2] Financial Performance - The net cash flow from operating activities was 965 million yuan, a growth of 4.70%, with the second quarter generating 1.27 billion yuan [1] - Dong'e Ejiao plans to distribute a cash dividend of 12.69 yuan per 10 shares, totaling approximately 817 million yuan, which accounts for 99.94% of the net profit attributable to shareholders for the first half of 2025 [1] Market Position - As of the first quarter of 2025, Dong'e Ejiao held a market share of 67.3% in the donkey-hide gelatin block category and 31.9% in the compound donkey-hide gelatin oral liquid market [1] - The revenue from donkey-hide gelatin and related products was 2.845 billion yuan, reflecting a year-on-year increase of 11.50% [2] Strategic Initiatives - The company is enhancing its brand through high-end and youth-oriented strategies, with stable sales performance in the OTC market [2] - Dong'e Ejiao is advancing its digital transformation and AI applications, achieving smart production processes and a raw material loss rate of 0.8% in 2024 [2] Collaboration and Investment - China Resources Group is empowering Dong'e Ejiao through capital collaboration and industry chain integration, including a 1 billion yuan pharmaceutical investment fund [3] - Dong'e Ejiao has engaged in strategic cooperation with China Resources Longde to explore new paths for traditional Chinese medicine in international markets [3] Corporate Governance - The implementation of the first phase of the stock incentive plan and the mid-term dividend distribution is enhancing corporate governance and talent cohesion [4] - The company is transitioning from a traditional manufacturer to a "smart health service provider," aiming to build its own health ecosystem [4]

Industry Overview - The number of registered companies in China's Ejiao industry has shown a growth trend, with over 600 companies registered as of June 2025, and nearly 200 new companies added between 2016 and 2020 [1][3] - The production of Ejiao blocks in China is projected to increase, with an estimated production of 4,379 tons in 2024 [3] Supply Situation - The sales-to-production ratio of Dong'e Ejiao has been declining over the past three years, dropping from 100.9% in 2022 to 97.9% in 2024, indicating increased inventory pressure [5] Demand Scale - The market size of the Ejiao industry in China is expected to reach approximately 29.1 billion yuan in 2024, driven by rising disposable income and increased health awareness among consumers [7] Price Trends - The prices of Ejiao products from major brands like Dong'e Ejiao and Fupai Ejiao have remained stable, with Dong'e Ejiao priced at 2,700 yuan per kilogram and Fupai Ejiao at approximately 1,260 yuan per kilogram [9]

Summary of Jiuzhitang Conference Call Company Overview - **Company**: Jiuzhitang - **Industry**: Traditional Chinese Medicine (TCM) Key Points and Arguments Sales and Profit Trends - Jiuzhitang's sales and profits are expected to decline in 2024, primarily due to the significant drop in sales of key products, An Gong Niu Huang Wan and Ejiao Kuai, which account for over 80% of the decline [2][3] - The company anticipates that its performance in 2025 will be flat or slightly improved, depending on the recovery of sales and consumer demand in the second half of the year [2][3] Prescription Drug Growth - The sales of Shuxuetong injection have shown significant growth, with an expected increase of approximately 10% in 2024 and continued growth in 2025 [2][4] - Other prescription drugs, such as Tianma Gouteng Granules, are projected to have a market scale between 30 million to 50 million, indicating potential for good growth [2][5] Future Growth Expectations - Jiuzhitang expects to return to double-digit growth in its main business by 2026-2027, driven by lower raw material prices and improved gross margins due to the establishment of a medicinal material company [2][6] Clinical Trials and New Drug Development - The clinical trials for stroke indications have completed Phase 1B and Phase 2A, with data collection and analysis expected to be completed by mid-2026, and the entire trial anticipated to finish around 2029 [2][8] - For pulmonary alveolar proteinosis (PAP), all 10 cases for Phase 2A have been completed, with data organization expected in July-August, and Phase 2B trials to follow [2][9] - The company is also focusing on stem cell therapy for autism, with trials expected to conclude around 2029-2030, highlighting its social value [2][10] Market Potential - The market for stroke indications is estimated to reach at least 10 billion, while the market for PAP is projected to be around 1 billion [2][18] - Jiuzhitang is the only company in China conducting research on stroke indications, indicating a favorable market outlook [2][8] Advantages in Stem Cell Therapy - Jiuzhitang has established a strong position in the stem cell therapy market, focusing on unique indications such as stroke, PAP, and autism, with significant expert and patient resources [2][11] - The company has invested in production capabilities and quality control, ensuring high standards in stem cell drug production [2][12][13] Regulatory Environment - The regulatory environment for stem cell therapy is becoming more favorable, with supportive policies emerging to facilitate clinical trials and commercialization [2][20] - The company plans to leverage its technology through licensing and patents for potential overseas market entry [2][23] Future Outlook - Jiuzhitang is optimistic about its future growth, with expectations of a rebound in 2025 and continued expansion in the coming years, supported by its solid industrial foundation and innovative drug development [2][27]

Group 1: Share Repurchase and Market Strategy - The company plans to continue researching share repurchase as a tool for market confidence and stock price stability, focusing on high dividend payouts as a primary investor return method [1] - The company aims to enhance brand engagement with younger consumers through product innovation and cultural initiatives, including the launch of convenient packaging and live streaming for targeted outreach [1] Group 2: Water Source Protection - The local government prioritizes the protection of the underground water source, which is rich in trace elements, ensuring high-quality and sustainable water supply through strict testing [2] Group 3: Pricing and Product Strategy - A systematic pricing governance plan is being implemented to create a sustainable pricing ecosystem for core products, transitioning from reliance on price increases to structural growth [3] - The company will dynamically adjust product prices based on supply and demand, optimizing pricing mechanisms for different consumer habits and product innovations [6] Group 4: Management and Strategic Execution - The management team will remain stable and committed to executing the "1238" strategy for steady business development [4] Group 5: Raw Material Supply Assurance - A dual-circulation raw material supply system is established, ensuring stable supply from domestic and international sources, while enhancing the utilization rate of donkey skin through research collaborations [5] Group 6: New Product Development - The company is focusing on the "Muntjac deer industry" and "Cistanche development" as new product directions, aiming for growth in high-potential segments [7]

Group 1 - Kanghong Pharmaceutical's Shugan Jieyu capsules achieved double-digit growth year-on-year, surpassing the overall growth of the antidepressant market [1] - The capsules have advantages such as faster efficacy, fewer side effects, and high long-term safety, which alleviate patients' psychological burden [1] - Clinical research for anxiety disorders is progressing steadily, with Phase III clinical trial enrollment expected to be completed by April 2025, potentially expanding the target population [1] Group 2 - Dong'e Ejiao emphasized the importance of sustainable supply of donkey hide, with current prices remaining stable [2] - In 2024, the revenue share of Ejiao blocks is approximately 45%, while the revenue share of compound Ejiao paste is nearly 35% [2] - The price of donkey hide is influenced by various factors, including breeding costs, scale, and import conditions [2] Group 3 - Hengrui Medicine launched a global public offering of 224.52 million H-shares, with a price range set between HKD 41.45 and HKD 44.05 per share [3] - The offering includes a 5.5% allocation for public sale in Hong Kong and 94.5% for international placement [3] - Seven cornerstone investors have subscribed for over HKD 4.1 billion (approximately USD 533 million), accounting for 43.04% of the offering size [3] Group 4 - Pianzaihuang reported that the current domestic market price for cow bile is between RMB 1.65 million and RMB 1.8 million per kilogram [4] - The company is actively engaging with policies regarding the import of cow bile, currently only allowing imports from Argentina [4] - The new import policy has minimal short-term impact on domestic cow bile prices, with no detailed guidance from government authorities yet [4] Group 5 - Changchun High-tech is in Phase III clinical trials for adult growth hormone deficiency indications [5] - The company maintains a rational attitude towards the sales growth of growth hormone products, focusing on stability and market expansion [5] - Research on the combination of semaglutide for muscle gain and fat loss is in the Investigator Initiated Trial phase [5] Group 6 - Kangzhi Pharmaceutical is preparing for the resumption of production for its Re Yan Ning granules, expected to be launched in the market by July-August this year [6] - The company is committed to the development of traditional Chinese medicine, enhancing existing products through secondary development [6] Group 7 - ST Huluwawa is leveraging the advantages of the Hainan Free Trade Port policy to establish a cross-border e-commerce platform [7] - The company aims to enhance operational efficiency and focus on the children's health consumption market [7] - A comprehensive O2O and online channel platform is being constructed to support product market coverage [7]

Group 1: Future Business Strategy - Dong-E E-Jiao will adhere to the "1238" strategy, focusing on the integration of the gelatin industry chain and enhancing its core business [1] - The company aims to improve digital capabilities and drive high-quality growth, aspiring to become a trusted leader in health supplements [1] Group 2: Investment and Acquisition Plans - Investment and acquisitions are key components of the "1238" strategy, with a focus on potential targets in the health supplement sector [1] - The company is implementing a "dual-wheel drive" strategy for investment direction, particularly in pharmaceuticals and health consumer products [2] Group 3: Raw Material Supply Assurance - The company emphasizes the sustainable supply of donkey hide, focusing on both domestic and international markets [3] - Efforts include establishing a supply network and promoting policy guidance in key countries to ensure a stable supply chain [3] Group 4: New Product Development - The "Zhuangben" brand will focus on upstream material acquisition and introduce innovative products to the market [4] - The company plans to enhance brand recognition for "Ejiao Dates" and develop a variety of health snack products [4] - A new category for "Ejiao Bird's Nest" will be created, with a focus on brand optimization and product efficacy verification [4] Group 5: Profit Distribution and Dividends - Since its listing in 1996, the company has distributed dividends 26 times, totaling 8.469 billion yuan, with an average payout ratio of 65.75% [6] - For 2024, the company plans to distribute 818 million yuan, with a payout ratio of 99.87% [6] Group 6: Revenue Projections - In 2024, Dong-E E-Jiao block products are expected to account for approximately 45% of total revenue, while compound Ejiao syrup is projected to contribute nearly 35% [6] Group 7: Brand Development Initiatives - The "Royal Weichang 1619" brand aims to establish itself as a leading men's health brand, focusing on product and category expansion [7] - The "Peach Blossom Princess Ejiao Cake" brand will undergo a comprehensive brand renewal to capture the mainstream beauty market [7] Group 8: Financial Performance Insights - The company experienced a decline in cash flow and an increase in accounts receivable due to strategic credit management and increased procurement of raw materials [8]

Core Insights - The company is focusing on its product segmentation, with approximately 45% of revenue coming from traditional Ejiao blocks and nearly 35% from compound Ejiao syrup in 2024 [1] - The brand Royal Weichang 1619 aims to strengthen its position in the men's health sector, emphasizing a vision of upgrading the Northeast industry and focusing on key strategies for brand and product development in 2025 [1] - The company is committed to ensuring a stable supply of donkey hides, which are crucial for its production, while maintaining a balance between domestic and international sourcing [1] Financial Performance - In the first quarter, the company reported good terminal sales performance and reassessed its strategic credit support based on the scale of cooperation with strategic clients [2] - The accounts receivable increased compared to the beginning of the year, but the management indicated that the sales collection and accounts receivable levels remain reasonable and controllable [2] - The company plans to maintain its established credit management strategy to ensure a healthy level of accounts receivable [2] Strategic Initiatives - The company is enhancing its brand strategy for the "Peach Blossom Princess" line, focusing on revitalizing the brand and establishing its position in the beauty and health market [1] - The management is increasing the procurement of strategic materials such as donkey hides and traditional Chinese medicinal herbs, which has led to higher capital expenditures [2] - The company expects to see an increase in cash flow from operations as bank acceptance bills mature and collections improve [2]